Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded
NEWS 22	Jul 02	FOREGE no longer contains STANDARDS file segment

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:55:11 ON 11 JUL 2002

=> fil reg

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'REGISTRY' ENTERED AT 11:56:40 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:     9 JUL 2002  HIGHEST RN 437979-76-5
DICTIONARY FILE UPDATES:    9 JUL 2002  HIGHEST RN 437979-76-5

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e gastrin?
E1            1     GASTRIMUT/BI
E2          636     GASTRIN/BI
E3            0 --> GASTRIN?/BI
E4            1     GASTRIPON/BI
E5            1     GASTRIX/BI
E6            1     GASTRIXON/BI
E7            1     GASTRIXONE/BI
E8           23     GASTRO/BI
E9            1     GASTROBAM/BI
E10           1     GASTROBAMATE/BI
E11           1     GASTROCALCI/BI
E12           1     GASTROCALCIN/BI

=> s e2
L1          636 GASTRIN/BI

=> e bombesin?
E1           63     BOMBESIA/BI
E2          298     BOMBESIN/BI
E3            0 --> BOMBESIN?/BI
E4            5     BOMBESINATO/BI
E5            1     BOMBETES/BI
E6           88     BOMBI/BI
E7            2     BOMBIC/BI
E8            1     BOMBICCITE/BI
E9            2     BOMBICOL/BI
E10           2     BOMBICOLA/BI
E11           5     BOMBIFORM/BI
E12           5     BOMBIFORMIS/BI

=> s e2
L2          298 BOMBESIN/BI

=> s l1 and l2
L3            8 L1 AND L2

=> fil .search
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	8.38	9.01

FILE 'MEDLINE' ENTERED AT 11:57:12 ON 11 JUL 2002

FILE 'CAPLUS' ENTERED AT 11:57:12 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BIOSIS' ENTERED AT 11:57:12 ON 11 JUL 2002

FILE 'USPATFULL' ENTERED AT 11:57:12 ON 11 JUL 2002

FILE 'EMBASE' ENTERED AT 11:57:12 ON 11 JUL 2002


```
=> s l3
L4        4305 L3

=> s l4 and (chelat? or ligand?)
L5         356 L4 AND (CHELAT? OR LIGAND?)

=> s l5 and (metal or metals)
L6          32 L5 AND (METAL OR METALS)

=> s l6 and (bombesin(p)agonist?)
L7           3 L6 AND (BOMBESIN(P) AGONIST?)

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8           3 DUP REM L7 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y
```

L8 ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 2002:105653 USPATFULL
TITLE: Gastrin receptor-avid peptide conjugates
INVENTOR(S): Hoffman, Timothy J., Columbia, MO, UNITED STATES
Volkert, Wynn A., Columbia, MO, UNITED STATES
Sieckman, Gary, Ashland, MO, UNITED STATES
Smith, Charles J., Columbia, MO, UNITED STATES
Gali, Hariprasad, Columbia, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002054855	A1	20020509
APPLICATION INFO.:	US 2001-847134	A1	20010502 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-537423, filed on 29 Mar 2000, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Kohn & Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI, 48334
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 2720
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful **metal** attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a **metal chelated** with a **chelating** group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a **metal** synthon with a **chelating** group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

L8 ANSWER 2 OF 3 USPATFULL
ACCESSION NUMBER: 97:104440 USPATFULL
TITLE: Polypeptide derivatives
INVENTOR(S): Albert, Rainer, Basel, Switzerland
Bauer, Wilfried, Lampenberg, Switzerland
Pless, Janos, Basel, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5686410		19971111
APPLICATION INFO.:	US 1994-276280		19940718 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-17723, filed on 16 Feb
1993, now abandoned which is a continuation of Ser. No.
US 1991-671763, filed on 18 Mar 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-16597	19890720
	GB 1990-4258	19900226
	GB 1990-5295	19900309

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Prickril, Benet
LEGAL REPRESENTATIVE: Borovian, Joseph J., Kassenoff, Melvyn M.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one **chelating** group linked to an amino group of said peptide, the **chelating** group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.

L8 ANSWER 3 OF 3 USPATFULL
ACCESSION NUMBER: 95:58122 USPATFULL
TITLE: Bombesin analogs
INVENTOR(S): Edwards, Judson V., Cincinnati, OH, United States
Fanger, Bradford O., Cincinnati, OH, United States
PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals Inc., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5428019		19950627
APPLICATION INFO.:	US 1994-213378		19940314 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-88413, filed on 16 Jul
1993, now abandoned which is a continuation of Ser. No.
US 1991-704863, filed on 23 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Jill
ASSISTANT EXAMINER: Davenport, A. M.
LEGAL REPRESENTATIVE: Collier, Kenneth J.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Agonists** and Antagonist of **bombesin** are derivatives of naturally occurring **bombesin** possessing a methyl sulfide or a methyl amide bond connecting the two amino acids on the carboxy terminal end. **Agonist** and antagonist activities are confirmed using conventional competitive binding and biochemical assays as well as conventional physiological tests and the use of these derivatives in a variety of conditions. Use of these peptides include stimulating or antagonizing growth of tissues, especially lung, and a means for effecting treatment for digestional disorders. Treatment comprises administering to a patient in need thereof, an effective amount of a **bombesin** analog.

```
=> s l6 not l7
L9          29 L6 NOT L7

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10          24 DUP REM L9 (5 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y
```

L10 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:353971 CAPLUS
DOCUMENT NUMBER: 136:365879
TITLE: Gastrin receptor-avid peptide conjugates and radionuclide complexes
INVENTOR(S): Hoffman, Timothy J.; Volkert, Wynn A.; Sieckman, Gary;
Smith, Charles J.; Gali, Hariprasad
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 537,423.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002054855	A1	20020509	US 2001-847134	20010502

PRIORITY APPLN. INFO.: US 2000-537423 A2 20000329

AB A compd. for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful **metal** attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amt. of a radiopharmaceutical having a **metal chelated** with a **chelating** group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compd. includes reacting a **metal** synthon with a **chelating** group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor. Numerous examples are provided of the prepn., properties, gastrin releasing peptide receptor affinity, tumor uptake and biodistribution of DOTA radionuclide complexes conjugated to bombesin(7-14)NH2 via linkers such as 5-aminovaleric acid and 8-aminooctanoic acid.

L10 ANSWER 2 OF 24 USPATFULL
ACCESSION NUMBER: 2002:85540 USPATFULL
TITLE: STABILIZED PROTEIN CRYSTALS FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM
INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, UNITED STATES
KHALAF, NAZAR K., WORCESTER, MA, UNITED STATES
CLAIR, NANCY L. ST., ANN ARBOR, MI, UNITED STATES
RAKESTRAW, SCOTT L., NEWARK, DE, UNITED STATES
SHENOY, BHAMI C., WOBURN, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045582	A1	20020418
APPLICATION INFO.:	US 1999-374132	A1	19990810 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-US9099, filed on 27 Apr 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-224475, filed on 31 Dec 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83148P	19980427 (60)
	US 1997-70274P	19971231 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARGARET A PIERRI, FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 100201104
NUMBER OF CLAIMS: 187
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 4131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition. The formulations and compositions enhance preservation of the native biologically active tertiary structure of the proteins and create a reservoir which can slowly release active protein where and when it is needed. Methods are provided preparing stabilized formulations using pharmaceutical ingredients or excipients and optionally encapsulating them in a polymeric carrier to produce compositions and using such protein crystal formulations and compositions for biomedical applications, including delivery of therapeutic proteins and vaccines. Additional uses for the protein crystal formulations and compositions of this invention involve protein

L10 ANSWER 2 OF 24 USPATFULL (Continued)
delivery in human food, agricultural feeds, veterinary compositions, diagnostics, cosmetics and personal care compositions.

L10 ANSWER 3 OF 24 USPATFULL
ACCESSION NUMBER: 2001:173335 USPATFULL
TITLE: Systematic evolution of **ligands** by exponential enrichment: Chemi-SELEX
INVENTOR(S): Gold, Larry, Boulder, CO, United States
Eaton, Bruce, Boulder, CO, United States
Smith, Drew, Boulder, CO, United States
Wecker, Matthew, Boulder, CO, United States
Jensen, Kirk, Boulder, CO, United States
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6300074	B1	20011009
APPLICATION INFO.:	US 1999-412017		19991004 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-460888, filed on 5 Jun 1995, now patented, Pat. No. US 5962219 Continuation of Ser. No. US 1995-400440, filed on 8 Mar 1995, now patented, Pat. No. US 5705337 Continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 Continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned , said Ser. No. US 714131 And Ser. No. US 412017 Continuation-in-part of Ser. No. US 1994-309245, filed on 20 Sep 1994, now patented, Pat. No. US 5723282 Continuation-in-part of Ser. No. US 1994-234997, filed on 28 Apr 1994, now patented, Pat. No. US 5683867 Continuation-in-part of Ser. No. US 1994-199507, filed on 22 Feb 1994, now patented, Pat. No. US 5472841 Continuation-in-part of Ser. No. US 1993-123935, filed on 17 Sep 1993, now abandoned Continuation-in-part of Ser. No. US 1993-117991, filed on 8 Sep 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Zitomer, Stephanie
LEGAL REPRESENTATIVE: Swanson & Bratschun, L.L.C.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 1693
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application provides methods for identifying nucleic acid **ligands** capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.

L10 ANSWER 4 OF 24 USPATFULL
ACCESSION NUMBER: 2001:158016 USPATFULL
TITLE: Systematic evolution of **ligands** by exponential enrichment: photoselection of nucleic acid **ligands** and solution selex
INVENTOR(S): Gold, Larry, Boulder, CO, United States
Willis, Michael, Louisville, CO, United States
Koch, Tad, Boulder, CO, United States
Ringquist, Steven, Lyons, CO, United States
Jensen, Kirk, Boulder, CO, United States
Atkinson, Brent, Boulder, CO, United States
PATENT ASSIGNEE(S): SomaLogic, Inc., Boulder, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291184	B1	20010918
APPLICATION INFO.:	US 1999-459553		19991213 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-93293, filed on 8 Jun 1998, now patented, Pat. No. US 6001577 Continuation of
Ser. No. US 612895, now patented, Pat. No. US 5763177 Continuation-in-part of Ser. No. US 1993-123935, filed on 17 Sep 1993, now abandoned Continuation-in-part of Ser. No. US 1993-143564, filed on 25 Oct 1993, now abandoned Continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 Continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned , said
Ser. No. US 612895 Continuation-in-part of Ser. No. US 1992-931473, filed on 17 Aug 1992, now patented, Pat. No. US 5270163 Division of Ser. No. US 714131
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Zitomer, Stephanie
LEGAL REPRESENTATIVE: Swanson & Bratschun, L.L.C.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 2330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for identifying nucleic acid **ligands** to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid **ligands** identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.

L10 ANSWER 5 OF 24 USPATFULL
ACCESSION NUMBER: 2001:29329 USPATFULL
TITLE: Recombinant expression of proteins from secretory cell lines
INVENTOR(S): Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwell, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6194176	B1	20010227
APPLICATION INFO.:	US 1997-785271		19970117 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campbell, Eggerton A.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT: 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.

L10 ANSWER 6 OF 24 USPATFULL
ACCESSION NUMBER: 2000:87959 USPATFULL
TITLE: Recombinant expression of proteins from secretory cell lines
INVENTOR(S): Newgard, Christopher B., Dallas, TX, United States
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwall, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
PATENT ASSIGNEE(S): Betagene, Inc., Dallas, TX, United States (U.S. corporation)
Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6087129		20000711
APPLICATION INFO.:	US 1996-589028		19960119 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campbell, Eggerton A.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 6238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.

L10 ANSWER 7 OF 24 USPATFULL
ACCESSION NUMBER: 1999:121122 USPATFULL
TITLE: Systematic evolution of **ligands** by exponential enrichment: chemi-selex
INVENTOR(S): Gold, Larry, Boulder, CO, United States
Eaton, Bruce, Boulder, CO, United States
Smith, Drew, Boulder, CO, United States
Wecker, Matthew, Boulder, CO, United States
Jensen, Kirk, Boulder, CO, United States
PATENT ASSIGNEE(S): NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962219		19991005
APPLICATION INFO.:	US 1995-460888		19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-117991, filed on 8 Sep 1993, now abandoned Ser. No. Ser. No. US 1993-123935, filed on 17 Sep 1993, now abandoned Ser. No. Ser. No. US 1994-199507, filed on 22 Feb 1994, now patented, Pat. No. US 5472841 Ser. No. Ser. No. US 1994-234997, filed on 28 Apr 1994, now patented, Pat. No. US 5683687 And Ser. No. US 1994-309245, filed on 20 Sep 1994, now patented, Pat. No. US 5723289 And a continuation of Ser. No. US 1995-400440, filed on 8 Mar 1995, now patented, Pat. No. US 5705337 which is a continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 2448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application provides methods for identifying nucleic acid **ligands** capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.

L10 ANSWER 8 OF 24 USPATFULL
ACCESSION NUMBER: 1999:7242 USPATFULL
TITLE: Flow cell SELEX
INVENTOR(S): Schneider, Daniel J., Broomfield, CO, United States
Vanderslice, Rebecca, Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
PATENT ASSIGNEE(S): NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5861254		19990119
APPLICATION INFO.:	US 1997-792075		19970131 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are methods for improved partitioning between high and low affinity nucleic acid **ligands** identified through the SELEX method, termed Flow Cell SELEX. The Flow Cell SELEX method achieves partitioning between high and low affinity nucleic acid **ligands** using surface plasmon resonance technology. The method of the present invention presents a new and powerful approach to select nucleic acid **ligands** by providing a partitioning method which 1) enables a significant increase in the efficiency of partitioning from traditional partitioning methods used in SELEX, 2) allows for real time monitoring of the partitioning of the high affinity **ligands** from the low affinity **ligands** 3) allows for the ability to select for a nucleic acid **ligand** having specific kinetic properties, 4) does not rely on radiolabeling or other means of tagging for detection, and 5) allows for use of smaller amounts of target than in traditional methods of SELEX.

L10 ANSWER 9 OF 24 USPATFULL
ACCESSION NUMBER: 1998:138866 USPATFULL
TITLE: Compounds and pharmaceutical uses of peptides of bombesin and GRP
INVENTOR(S): Krstenansky, John L., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Merrell Pharmaceuticals Inc., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834433		19981110
APPLICATION INFO.:	US 1996-960130		19960223 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-447528, filed on 23 May 1995, now abandoned which is a continuation of Ser. No. US 1994-278692, filed on 21 Jul 1994, now abandoned which is a continuation of Ser. No. US 1991-735402, filed on 24 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-558031, filed on 26 Jul 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Payne, T. Helen
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for controlling the growth of tumor tissues, especially small cell lung. Treatment comprises administering to a patient in need thereof, an effective amount of a bombesin/GRP type inhibitor.

Antagonists of bombesin/GRP which are derivatives of naturally occurring bombesin/GRP possessing a thiomethylene or methylene sulfoxide bond connecting the two amino acids on the carboxy terminal end is modified are described. The antagonism is confirmed using conventional competitive binding and biochemical assays as well as conventional physiological tests and the use of these derivatives in a variety of conditions in which bombesin/GRP is implicated is also described.

L10 ANSWER 10 OF 24 USPATFULL
ACCESSION NUMBER: 1998:91791 USPATFULL
TITLE: Parallel selex
INVENTOR(S): Eaton, Bruce E., Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
PATENT ASSIGNEE(S): NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789160		19980804
APPLICATION INFO.:	US 1995-463101		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-309245, filed on 20 Sep 1994 which is a continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1986
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention disclosures a method for coevolving products from two or more reactants, along with the nucleic acid that can facilitate the reaction for making the products. The invention further discloses the products and facilitating nucleic acids produced by said method.

L10 ANSWER 11 OF 24 USPATFULL
ACCESSION NUMBER: 1998:65372 USPATFULL
TITLE: Systematic evolution of **ligands** by exponential enrichment: Chemi-SELEX
INVENTOR(S): Gold, Larry, Boulder, CO, United States
Eaton, Bruce, Boulder, CO, United States
Smith, Drew, Boulder, CO, United States
Wecker, Matthew, Boulder, CO, United States
Jensen, Kirk, Boulder, CO, United States
PATENT ASSIGNEE(S): NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5763595		19980609
APPLICATION INFO.:	US 1995-463093		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-400440, filed on 8 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-309245, filed on 20 Sep 1994, now patented, Pat. No. US 5723289 Ser. No. Ser. No. US 1994-234997, filed on 28 Apr 1994, now patented, Pat. No. US 5683867 Ser. No. Ser. No. US 1994-199507, filed on 22 Feb 1994, now patented, Pat. No. US 5472841 Ser. No. Ser. No. US 1993-123935, filed on 17 Sep 1993, now abandoned And Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 2183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application provides methods for identifying nucleic acid **ligands** capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.

L10 ANSWER 12 OF 24 USPATFULL
ACCESSION NUMBER: 1998:22351 USPATFULL
TITLE: Parallel selex
INVENTOR(S): Eaton, Bruce E., Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
PATENT ASSIGNEE(S): NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5723592		19980303
APPLICATION INFO.:	US 1995-462389		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-309245, filed on 20 Sep 1994 which is a continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for coevolving products from two or more reactants, along with the nucleic acid that can facilitate the reaction for making the products. The invention further discloses the products and facilitating nucleic acids produced by said method.

L10 ANSWER 13 OF 24 USPATFULL
ACCESSION NUMBER: 1998:4744 USPATFULL
TITLE: Thioether conjugates
INVENTOR(S): Willner, David, Hamden, CT, United States
Trail, Pamela A., Farmington, CT, United States
King, H. Dalton, Hamden, CT, United States
Hofstead, Sandra J., Middletown, CT, United States
Greenfield, Robert S., Wallingford, CT, United States
Braslawsky, Gary R., Glastonbury, CT, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5708146		19980113
APPLICATION INFO.:	US 1995-469840		19950606 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-824951, filed on 23 Jan 1992, now patented, Pat. No. US 5622929
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Peselev, Elli
LEGAL REPRESENTATIVE: Poor, Brian, Sorrentino, Joseph M., Savitsky, Thomas R.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 2044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are drug/**ligand** compounds of Formula (I): ##STR1## (I) in which

D is a drug moiety;

n is an integer from 1 to 10;

p is an integer from 1 to 6;

Y is O or NH.sub.2.sup.+ Cl.sup.- ;

z is 0 or 1;

q is about 1 to about 10;

X is a **ligand**; and,

A is a Michael Addition Adduct.

In a preferred embodiment, the **ligand** is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.

L10 ANSWER 14 OF 24 USPATFULL
ACCESSION NUMBER: 1998:1626 USPATFULL
TITLE: Systematic evolution of **ligands** by exponential enrichment: chemi-SELEX
INVENTOR(S): Gold, Larry, Boulder, CO, United States
Eaton, Bruce, Boulder, CO, United States
Smith, Drew, Boulder, CO, United States
Wecker, Matthew, Boulder, CO, United States
Jensen, Kirk, Boulder, CO, United States
PATENT ASSIGNEE(S): NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5705337		19980106
APPLICATION INFO.:	US 1995-400440		19950308 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-117991, filed on 8 Sep 1993, now abandoned Ser. No. Ser. No. US 1993-123935, filed on 17 Sep 1993, now abandoned Ser. No. Ser. No. US 1994-199507, filed on 22 Feb 1994, now patented, Pat. No. US 5472841 Ser. No. Ser. No. US 1994-234997, filed on 28 Apr 1994 Ser. No. Ser. No. US 1994-309245, filed on 20 Sep 1994 And Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 2208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application provides methods for identifying nucleic acid **ligands** capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.

L10 ANSWER 15 OF 24 USPATFULL
ACCESSION NUMBER: 97:33724 USPATFULL
TITLE: Thioether conjugates
INVENTOR(S): Willner, David, Hamden, CT, United States
Trail, Pamela A., Farmington, CT, United States
King, H. Dalton, Hamden, CT, United States
Hofstead, Sandra J., Middletown, CT, United States
Greenfield, Robert S., Wallingford, CT, United States
Braslawsky, Gary R., Glastonbury, CT, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5622929		19970422
APPLICATION INFO.:	US 1992-824951		19920123 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Peselev, Elli		
LEGAL REPRESENTATIVE:	Bristol-Myers Squibb Co.		
NUMBER OF CLAIMS:	52		
EXEMPLARY CLAIM:	6		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	2212		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are drug/**ligand** compounds of Formula (I): ##STR1## in which D is a drug moiety;

n is an integer from 1 to 10;

p is an integer from 1 to 6;

Y is O or NH.sub.2.sup.+ Cl.sup.- ;

z is 0 or 1;

q is about 1 to about 10;

X is a **ligand**; and,

A is a Michael Addition Adduct.

In a preferred embodiment, the **ligand** is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.

L10 ANSWER 16 OF 24 USPATFULL
ACCESSION NUMBER: 97:20221 USPATFULL
TITLE: Treatment methods using **metal**-binding targeted polypeptide constructs
INVENTOR(S): Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Coughlin, Daniel J., Robbinsville, NJ, United States
Alvarez, Vernon L., Morrisville, PA, United States
Wood, Richard, Rocky Hill, NJ, United States
PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5609847		19970311
APPLICATION INFO.:	US 1995-480370		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-127351, filed on 28 Sep 1993, now patented, Pat. No. US 5449761		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Lowe, Price, LeBlanc & Becker		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1775		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of treating a patient in need thereof, including a need for diagnosis or treatment, comprising the administration of a **metal** complex of a polypeptide construct. The construct comprises a compound of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone,

"P" is a polypeptide capable of targeting particular-cells, tissues or organs of the body,

"A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group,

R, R', and R" may be the same or different and may be hydrogen or an aliphatic group,

m is an integer .gtoreq.2, provided that the groups R, R', R", L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain,

n is an integer .gtoreq.0;

or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

L10 ANSWER 17 OF 24 USPATFULL
ACCESSION NUMBER: 97:16169 USPATFULL
TITLE: Thioether conjugates
INVENTOR(S): Willner, David, Hamden, CT, United States
Trail, Pamela A., Farmington, CT, United States
King, H. Dalton, Hamden, CT, United States
Hofstead, Sandra J., Middletown, CT, United States
Greenfield, Robert S., Wallingford, CT, United States
Braslawsky, Gary R., Glastonbury, CT, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5606017		19970225
APPLICATION INFO.:	US 1995-468162		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-824951, filed on 23 Jan 1992		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Peselev, Elli		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	2095		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are drug/**ligand** compounds of Formula (I): ##STR1## in which D is a drug moiety;

n is an integer from 1 to 10;

p is an integer from 1 to 6;

Y is O or NH.sub.2.sup.+ Cl.sup.- ;

z is 0 or 1;

q is about 1 to about 10;

X is a **ligand**; and,

A is a Michael Addition Adduct.

In a preferred embodiment, the **ligand** is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.

L10 ANSWER 18 OF 24 USPATFULL
ACCESSION NUMBER: 97:3508 USPATFULL
TITLE: **Metal**-binding targeted polypeptide constructs
INVENTOR(S): Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Coughlin, Daniel J., Robbinsville, NJ, United States
Alvarez, Vernon L., Morrisville, PA, United States
Wood, Richard, Rocky Hill, NJ, United States
PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5593656		19970114
APPLICATION INFO.:	US 1995-487221		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-127351, filed on 28 Sep 1993, now patented, Pat. No. US 5449761		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Jones, D. L.		
LEGAL REPRESENTATIVE:	Lowe, Price, LeBlanc & Becker		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1808		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both **metal**-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tisaues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R", L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer.gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

L10 ANSWER 19 OF 24 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 97411499 MEDLINE
DOCUMENT NUMBER: 97411499 PubMed ID: 9266477
TITLE: NMR structure of neuromedin C, a neurotransmitter with an amino terminal CuII-, NiII-binding (ATCUN) motif.
AUTHOR: Gaemi G; Singer A; Forman-Kay J; Sarkar B
CORPORATE SOURCE: Department of Biochemistry Research, Hospital for Sick Children, Toronto, Ontario, Canada.
SOURCE: JOURNAL OF PEPTIDE RESEARCH, (1997 Jun) 49 (6) 500-9. Journal code: 9707067. ISSN: 1397-002X.
PUB. COUNTRY: Denmark
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199710
ENTRY DATE: Entered STN: 19971021
Last Updated on STN: 19971021
Entered Medline: 19971009

AB The structure of neuromedin C, a 10-residue bombesin-like neuropeptide with the sequence Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been investigated. Like human serum albumin, neuromedin C contains the amino-terminal CuII-, NiII-binding (ATCUN) motif which has high affinity for CuII and NiII. The solution structure of the NiII-peptide complex has been calculated based on 2D ROESY data obtained at 25 degrees C, using a hybrid distance geometry-simulated annealing approach. Comparison of 1H, 13C and 15N chemical shifts and ROESY data in the presence and absence of NiII demonstrates that the **metal** binds at the N-terminus of the peptide, leading to a conformational change. The **metal** complex adopts a conformation comprising two connected turns including residues 1Gly to 3His and 5Ala to 8His. The first turn corresponds to the NiII coordination **ligands** in a square planar conformation, and the second reflects the interaction between 4Trp and 8His. The results may have important physiological implications in the phenomenon of neurotransmission.

L10 ANSWER 20 OF 24 USPATFULL
ACCESSION NUMBER: 96:108663 USPATFULL
TITLE: **Metal**-binding targeted polypeptide constructs
INVENTOR(S): Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Coughlin, Daniel J., Robbinsville, NJ, United States
Alvarez, Vernon L., Morrisville, PA, United States
Wood, Richard, Rocky Hill, NJ, United States
PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578288		19961126
APPLICATION INFO.:	US 1995-480367		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-127351, filed on 28 Sep 1993, now patented, Pat. No. US 5449761
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Lowe, Price, LeBlanc & Becker
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both **metal**-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tissues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'-- NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R", L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer.gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

L10 ANSWER 21 OF 24 USPATFULL
ACCESSION NUMBER: 96:96929 USPATFULL
TITLE: Systematic evolution of **ligands** by exponential enrichment: Solution SELEX
INVENTOR(S): Gold, Larry, Boulder, CO, United States
Ringquist, Steven, Boulder, CO, United States
PATENT ASSIGNEE(S): University Research Corporation, Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5567588		19961022
APPLICATION INFO.:	US 1995-461069		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-143564, filed on 25 Oct 1993 And a continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 And Ser. No. US 1992-931473, filed on 17 Aug 1992, now patented, Pat. No. US 5270163 And Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Swanson & Bartschun LLC
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are methods for improved partitioning between high and low affinity nucleic acid **ligands** identified through the SELEX method, termed solution SELEX. The solution SELEX method achieves partitioning between high and low affinity nucleic acid-target complexes through a number of methods, including (1) primer extension inhibition which results in differentiable cDNA products. Primer extension inhibition is achieved with the use of nucleic acid polymerases, including DNA or RNA polymerases, reverse transcriptase, and Q.beta.-replicase; (2) exonuclease hydrolysis inhibition which results in only the highest affinity **ligands** amplifying during PCR. This is achieved with the use of any 3'.fwdarw.5' double-stranded exonuclease; (3) linear to circle formation to generate molecules amplifiable during PCR; or (4) PCR amplification of single-stranded nucleic acids. A central theme of the method of the present invention is that the nucleic acid candidate mixture is screened in solution and results in preferential amplification of the highest affinity RNA **ligand** or catalytic RNA.

L10 ANSWER 22 OF 24 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 96213871 MEDLINE
DOCUMENT NUMBER: 96213871 PubMed ID: 8644999
TITLE: Extracellular zinc ions induces mitogen-activated protein kinase activity and protein tyrosine phosphorylation in bombesin-sensitive Swiss 3T3 fibroblasts.
AUTHOR: Hansson A
CORPORATE SOURCE: Department of Molecular Medicine, The Endocrine and Diabetes Unit, Karolinska Institutet, Stockholm, Sweden.
SOURCE: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (1996 Apr 15) 328 (2) 233-8. Journal code: 0372430. ISSN: 0003-9861.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199607
ENTRY DATE: Entered STN: 19960726
Last Updated on STN: 19980206
Entered Medline: 19960712

AB The growth factor-like effect of zinc in vitro and in vivo, which has long been recognized was investigated with respect to its mechanisms of action.
Addition of zinc chloride to bombesin-sensitive Swiss 3T3 mouse fibroblasts induced a fourfold stimulation in the cytosolic myelin basic protein kinase activity. The response was dose- and time-dependent, with an ED50 of around 100 microM and a peak at 5 min. The kinase activity coeluted with p42 MAP kinase using chromatography on Mono-Q ion exchange. Intracellular loading of cells with the heavy **metal** **chelator** BTC-5N did not attenuate the response to zinc. The action of zinc was not suppressed by long-term pretreatment with 4-beta-phorbol dibutyrate (48 h). Addition of 0.3 mM vanadate alone did not increase the kinase activity, but prolonged the action of zinc when added simultaneously. Addition of zinc (0.3 mM) or epidermal growth factor for 1 min resulted in a marked increase in tyrosine phosphorylation of proteins with apparent molecular weights of approximately 100, 105-120, 215, and 240 kDa in whole cell extracts. Immunoprecipitation against the p85 subunit of phosphatidylinositol 3-kinase resulted in the appearance of two phosphotyrosine-containing proteins, 100 and 115 kDa, in extracts from cells treated with zinc or epidermal growth factor, indicating that the tyrosine phosphorylation was recognized by the corresponding SH2-domains. The present study demonstrates that extracellular zinc has the potential to partially mimic the action of growth factors on intracellular MAP kinase activation and protein tyrosine phosphorylation.

L10 ANSWER 23 OF 24 USPATFULL
ACCESSION NUMBER: 95:82355 USPATFULL
TITLE: **Metal**-binding targeted polypeptide constructs
INVENTOR(S): Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Coughlin, Daniel J., Robbinsville, NJ, United States
Alvarez, Vernon L., Morrisville, PA, United States
Wood, Richard, Rocky Hill, NJ, United States
PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5449761		19950912
APPLICATION INFO.:	US 1993-127351		19930928 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Geist, Gary L.
ASSISTANT EXAMINER: Chapman, Lara E.
LEGAL REPRESENTATIVE: Lowe, Price, LeBlanc & Becker
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both **metal**-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tissues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R' and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer .gtoreq.2, provided that the groups R, R', R', L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer .gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

L10 ANSWER 24 OF 24 USPATFULL
ACCESSION NUMBER: 93:76501 USPATFULL
TITLE: Nonapeptide bombesin antagonists
INVENTOR(S): Cai, Renzhi, Metairie, LA, United States
Schally, Andrew V., Metairie, LA, United States
PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, New Orleans, LA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5244883		19930914
APPLICATION INFO.:	US 1990-619747		19901129 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Lester L.
ASSISTANT EXAMINER: Davenport, A. M.
LEGAL REPRESENTATIVE: Behr, Omri M., McDonald, Matthew J.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The novel pseudo polypeptides of this invention are potent bombesin antagonists. There are provided processes for their production, pharmaceutical compositions comprising said polypeptides and their use as pharmaceutically active agents. More particularly the present invention provides pseudopeptides comprising a nonapeptide moiety of formula I:

X-A.sup.1 -A.sup.2 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -.sub.psi -A.sup.9 -Q

wherein Q is NH.sub.2 or OQ.sup.1 where Q.sup.1 is hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.7-10 alkyl; X is hydrogen or a single bond linking to A.sup.2 the acyl residue of an organic acid, or a group of formula R.sup.1 CO-- wherein (1) R.sup.1 is hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.7-10 -alkyl; (2) R.sup.1 CO-- is (a) R.sup.2 N(R.sup.3)--CO-- wherein R.sup.2 is hydrogen, C.sub.1-10 alkyl, phenyl or C.sub.7-10 phenyl-C.sub.7-10 -alkyl, R.sup.3 is hydrogen or C.sub.1-10 alkyl; (b) R.sup.4 --O--CO-- wherein R.sup.4 is C.sub.1-10 alkyl, phenyl or phenyl-C.sub.7-10 -alkyl. A.sup.1 is D-, L- or DL-pGlu,, Nal, Phe, Thl, Tyr, Tpi, Hca, Hpp, Mpp, Trp or Trp substituted in the benzene ring by one or more members selected from the group consisting of halogen, NO.sub.2, NH.sub.2, OH, C.sub.1-3 alkyl and C.sub.1-3 alkoxy wherein halogen is fluorine, chlorine and bromine; wherein A.sup.2 -A.sup.7 and A.sup.9 are each amino acid residues; A.sup.8 is a reduced isostere of Leu or Phe.